Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 26 Years' experience in a patient cohort from a defined population area

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 9, 2005, Pages 1076-1080

  Lindberg, Jan ^a   Stenling, Roger ^b   Palmqvist, Richard ^b   Rutegård, Jörgen ^b,c  

^a Clinic of Ophthalmology   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal cancer; Dysplasia; Surveillance; Ulcerative colitis

Indexed keywords

ARTICLE; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; DYSPLASIA; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; POPULATION; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTESTINAL MUCOSA; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TIME FACTORS;

EID: 24744433281     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023224     Document Type: Article

References (22)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
2. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988;29:206-17.
3. Bruewer M, Kriegelstein CF, Utech M, Bode M, Rijcken E, Anthori L, et al. Is colonoscopy alone sufficient to screen for ulcerative colitis-associated colorectal carcinoma? World J Surg 2003;27:611-5.
4. Ullman TA, Loftus EV Jr, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002;97:922-7.
5. Lindberg B, Persson B, Veress B, Ingelman-Sundberg H, Granqvist S. Twenty years' colonoscopic surveillance of patients with ulcerative colitis. Detection of dysplastic and malignant transformation. Scand J Gastroenterol 1996;31:1195-204.
6. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson BCH. Factors affecting the outcome of endoscopie surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
7. Lindberg JO, Stenling RB, Rutegard JN. DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis. Br J Surg 1999;86:947-50.
8. Lofberg R, Brostrom O, Karlen P, Tribukait B, Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis: a 15-year follow-up study. Gastroenterology 1990;99:1021-31.
9. Holzmann K, Weis-Klemm M, Klump B, Hsieh CJ, Borchard F, Gregor M, et al. Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis. Scand J Gastroenterol 2001;36:1320-6.
10. Sjoqvist U, Ost A, Lofberg R. Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. Int J Colorectal Dis 1999;14:107-13.
11. Pohl C, Hombach A, Kruis W Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000;47:57-70.
12. Collins RH Jr, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review N Engl J Med 1987;316:1654-8.
13. Lynch DA, Lobo AJ, Sobala GM, Dixon MF, Axon AT. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993;34:1075-80.
14. Rutegard J, Ahsgren L, Stenling R, Janunger KG. Ulcerative colitis. Cancer surveillance in an unselected population. Scand J Gastroenterol 1988;23:139-45.
15. Jonsson B, Ahsgren L, Andersson LO, Stenling R, Rutegard J. Colorectal cancer surveillance in patients with ulcerative colitis. Br J Surg 1994;81:689-91.
16. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Feneglio CM, Haggit RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
17. Lindberg JO, Stenling RB, Rutegard JN. Eighteen-year surveillance of dysplasia-associated lesion in ulcerative colitis. Endoscopy 2000;32:359-60.
18. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology 1992;103:431-8.
19. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002;17:1078-83.
20. Biasco G, Rossini FP, Hakim R, Bianchi G, Di Battista M, Di Febo G, et al. Cancer surveillance in ulcerative colitis: critical analysis of a long-term prospective programme. Dig Liver Dis 2002;34:339-42.
21. Rhodes JM. Surveillance for colitis-associated cancer: we cannot stop now. Dig Liver Dis 2002;34:319-21.
22. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998;42:711-4.